During the Reporting Period, the Group’s revenue increased by 29.1% to HK$743.0M.
Jacobson Pharma Announces FY2018 Interim ResultsRealizing Growth Strategies With Both Revenue and Net Profit Up; Declares Interim Dividend of HK0.9 cent per share HONG KONG, CHINA -- (Marketwired) -- Nov 22, 2017 -- Jacobson Pharma ( During the Reporting Period, the Group's revenue increased by 29.1% to HK$743.0 million (1H2016: HK$575.4 million). Gross profit and profit from operations rose by 14.0% to HK$278.9 million (1H2016: HK$244.6 million) and 43.9% to HK$112.7 million (1H2016: HK$78.3 million) respectively. Profit attributable to the shareholders of the Company surged by 40.6% to HK$80.3 million (1H2016: HK$57.1 million). Basic and diluted earnings per share were HK4.42 cents. The Group maintains a healthy financial position with cash and cash equivalents of HK$326.3 million at the end of the Reporting Period. The Board has declared payment of an interim dividend for the six months ended 30 September of HK0.9 cent per share (1H2016: HK0.8 cent). Business Review The Group is a market leader in a number of therapeutic categories and its research and development ("R&D") team has been progressively enriching the product pipeline to help fuel the Group's growth momentum in those categories. A noteworthy example is the recent launch of losartan which witnessed a robust sales growth of 87.5% during the Reporting Period. In terms of productivity, the Group's manufacturing operations continued to perform well affording a steady rise in production output. The total output of the three major product dosage forms -- solid, semi-solid and liquid -- grew respectively by 17.3% to 1,341 million tablets and capsules, 37.0% to 135 tons and 4.9% to 1,373 kilo-liters as compared to corresponding period of 2016. Proprietary Medicines The Group continues to contemplate geographical expansion into strategic markets in the Asia Pacific, such as Taiwan and certain ASEAN countries. It has put in place a dedicated business development team to pursue market evaluations and to expedite market entry and regulatory clearance. Wholesale and Retail Product Development The Group also made good progress on collaboration projects with various R&D institutions. Derived from the collaboration with Nano & Advanced Materials Institute Limited (NAMI), a commercialized product being trademarked as "NanoAZD™" was launched in April 2017. The product was first introduced at the Alzheimer's Association International Conference in London in July 2017 and received encouraging feedback as well as recognition for its potential in subsequent clinical application. Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, said, "We are delighted that Jacobson Pharma maintained healthy business momentum and executed the necessary growth strategies in line with our original plans and schedule for the first half of FY2018. Underpinning the financial results in the period under review is a continued focus on the key growth drivers, encompassing first-to-opportunity generics, such as losartan and mesalazine and proprietary brands, including Po Chai Pills, Ho Chai Kung and Shiling Oil. Looking ahead, we will continue to take measured and disciplined approach to R&D investment and capital allocation whilst expecting further progress with its development pipeline, offering potential value through multiple licensing opportunities on both generic drugs as well as biopharmaceuticals. We will continue to pursue expanding our footprint in certain strategic markets in Asia with a view to creating sustainable values for our shareholders." About Jacobson Pharma Corporation Limited (
For media enquiries, please contact: Strategic Financial Relations Limited Vicky Lee Tel: (852) 2864 4834 Email: Email Contact Angela Ng Tel: (852) 2864 4855 Email: Email Contact Angel Li Tel: (852) 2864 4859 Email: Email Contact |
